Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

medicine-field-of-study

Medicine (field Of Study), News on Medicine (field Of Study), stories on Medicine (field Of Study), articles on Medicine (field Of Study), Medicine (field Of Study) stories at Wion, Medicine (field Of Study) news, Medicine (field Of Study) latest news

medicine field-of-study

Lancet opens probe into ‘unreliable’ anti-stroke medicine